Exclusive Interview with 22nd Century Group CEO Jim Mish 22nd Century Group (NASDAQ: XXII) is a plant-based biotechnology that operates three business segments: tobacco, cannabis/hemp and hops. The company...

Exclusive Interview with Demetrix CEO Jeff Ubersax, PhD Biotechnology companies are hard at work finding ways to commercialize biosynthetic cannabinoids, and among those companies is Demetrix. CEO Jeff Ubersax...

Exclusive Interview with Hyasynth Co-Founder and CEO Kevin Chen Right now, traditional agricultural practices are the main production method of natural cannabinoids. It takes months to create a final...

Exclusive Interview with Infusion Biosciences Cofounder and CEO Arup Sen, PhD Cannabis biotech company Infusion Biosciences has developed technology that recovers cannabinoids, terpenes, and other molecules in the cannabis...